Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Stevanato Group SpA's 5-Year RORE % for the quarter that ended in Jun. 2026 was 2.04%.
The industry rank for Stevanato Group SpA's 5-Year RORE % or its related term are showing as below:
STVN's 5-Year RORE % is ranked better than 57.2% of 708
companies
in the Medical Devices & Instruments industry
Industry Median: -4.96
vs STVN: 2.04
Stevanato Group SpA (NYSE:STVN) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Stevanato Group SpA 5-Year RORE % Related Terms
Stevanato Group SpA 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Stevanato Group SpA's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA 5-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 5-year before.
Stevanato Group SpA (STVN) has a 5-Year RORE % of 2.04 as of Jun. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Stevanato Group SpA and its competitors. According to the industry distribution chart, Stevanato Group SpA ranks #303 out of 708 companies in the Medical Devices & Instruments industry, placing it in the top 42.8%.
Is Stevanato Group SpA's 5-Year RORE % too high?
Stevanato Group SpA's current 5-Year RORE % is 2.04. Based on the distribution chart, Stevanato Group SpA ranks #303 out of 708 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stevanato Group SpA has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's 5-Year RORE % compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #303 out of 708 companies for 5-Year RORE %. This puts Stevanato Group SpA in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Stevanato Group SpA and its competitors. Stevanato Group SpA's current 5-Year RORE % is 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (STVN) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.04, compared to a current price of $20.32 — trading 22% below its estimated fair value. The current 5-Year RORE % is 2.04. Stevanato Group SpA's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Stevanato Group SpA (STVN), the current 5-Year RORE % is 2.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (STVN) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of $20.32 is trading 22% below its estimated GF Value™ of $26.04.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for STVN:
5-Year RORE %: 2.04
GF Value™: $26.04 vs. price of $20.32 (22% below fair value)
No single metric tells the full story. See the STVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
86GF Score
Get the complete analysis for STVN
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STVN has been successfully added to your 
